Table 2 Univariate and multivariate analysis of overall survival and disease-free survival for patients with intrahepatic cholangiocarcinoma after PSM

Gender

Female vs Male

0.72(0.45–1.14)

0.158

0.77(0.51–1.16)

0.217

Age (y)

≤60 vs > 60

0.92(0.59–1.43)

0.706

0.71(0.48–1.06)

0.098

HBsAg

0.750

1.08(0.70–1.66)

0.738

ECOG score

≤2 vs > 2

1.00(0.64–1.55)

0.986

0.80(0.54–1.18)

0.255

CA19–9 (U/ml)

≤200 vs > 200

1.23(0.71–2.14)

0.458

0.88(0.53–1.47)

0.625

CEA (ng/ml)

≤5 vs > 5

1.03(0.63–1.67)

0.912

0.91(0.59–1.39)

0.653

Blood loss (ml)

≤400 vs > 400

1.02(0.61–1.71)

0.947

0.74(0.46–1.19)

0.216

Transfusion

No vs Yes

1.15(0.69–1.90)

0.600

0.61(0.37–1.02)

0.058

Laparoscopic approach

No vs Yes

Major hepatectomy

No vs Yes

1.34(0.84–2.15)

0.215

1.02(0.69–1.52)

0.920

Complications

No vs Yes

Resection margin (cm)

≤1 vs > 1

1.65(1.06–2.58)

0.026

1.60(1.03–2.50)

0.039

1.49(1.01–2.20)

0.046

Tumor size (cm)

≤5 vs > 5

1.33(0.85–2.08)

0.214

1.15(0.77–1.70)

0.497

Tumor number

Solitary vs Multiple

1.31(0.81–2.12)

0.267

1.14(0.73–1.80)

0.558

Lymph node invasion

No vs Yes

2.03(1.15–3.57)

0.014

2.24(1.27–3.95)

0.005

1.15(0.65–2.02)

0.638

Mass-forming

No vs Yes

1.17(0.73–1.87)

0.524

1.33(0.87–2.05)

0.187

Tumor differentiation

Well &Moderate vs Poor

1.33(0.85–2.08)

0.214

0.80(0.48–1.34)

0.399

Satellite

No vs Yes

1.27(0.77–2.11)

0.352

1.32(0.84–2.09)

0.231

MVI

No vs Yes

2.03(1.12–3.69)

0.02

2.42(1.39–4.22)

0.002

2.67(1.50–4.74)

0.001

Perineural invasion

No vs Yes

0.94(0.50–1.79)

0.860

0.69(0.38–1.26)

0.232

p-AT

No vs Yes

0.38(0.18–0.83)

0.016

0.39(0.18–0.85)

0.018

0.73(0.43–1.24)

0.244